Shares of Achieve Life Sciences surged 11.5% to $7.25 in pre-market trading on October 23, bucking a weaker broader market, after the company presented new year-long data showing its smoking- and vaping-cessation pill helped nearly one in three adults quit. The move marks a sharp reversal from weeks of selling that had pushed the stock down from above $8 in early October.
A 31% Quit Rate Sounds Good — but Context Matters
The 52-week trial showed 31.2% of participants achieved sustained smoking or vaping abstinence during the final four weeks of treatment.
That figure climbed from 25.5% at weeks 9–12 to 30.3% at weeks 21–24 , suggesting longer use improves outcomes. Among those who had been on placebo in a prior trial, the rate hit 39.4%. These are open-label results — meaning everyone knew they were getting the drug — so they can't be directly stacked against placebo-controlled benchmarks. Still, ICER has concluded cytisinicline has "similar efficacy but significantly fewer gastrointestinal side effects than varenicline," the current standard. That tolerability edge — nausea of just 2.5% over a full year — is the drug's core commercial selling point.
The Real Risk Isn't the Science — It's the Factory
The FDA's June 2026 rejection letter cited manufacturing problems at a former third-party facility and incomplete labeling — not clinical safety or efficacy concerns.
Achieve has since shifted production to Adare Pharma Solutions and plans to resubmit its application in Q4 2026.
A resubmission carries a six-month FDA review clock, pointing to a potential approval in the first half of 2027. One governance wrinkle: Adare's CEO sits on Achieve's board and chairs its compensation committee, a related-party arrangement investors should watch.
A ~$675 Million Bet Needs Approval to Pay Off
Achieve's market cap sits at roughly $671 million for a company with zero revenue and a $84.9 million net loss in the first half of 2026.
An April private placement raised $180 million upfront, with another $174 million in warrants triggered only upon FDA approval.
Analysts carry a consensus "Buy" rating with an average price target of $15.50 — more than double today's price — but that target is entirely conditional on the drug reaching pharmacies. The U.S. smoking-cessation market is valued at roughly $1.5 billion , and no new prescription therapy has been approved since 2006. Today's data bolsters the clinical case; the stock's fate now rests on a factory inspection.